Bilayer Tablet Formulations
Patent No. EP2498758 (titled "Bilayer Tablet Formulations") was filed by Astrazeneca on Nov 12, 2010. The application was issued on Jul 25, 2018.
Patent Summary
Bilayer tablet formulation for treating type 2 diabetes comprising a first layer of metformin extended release (XR) and a second layer of sodium-glucose transporter 2 (SGLT2) inhibitor, with optional film coating. The metformin XR layer is formulated with metformin hydrochloride, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and magnesium stearate. The SGLT2 inhibitor layer is formulated with dapagliflozin, lactose anhydrous, microcrystalline cellulose, crospovidone, silicon dioxide, and magnesium stearate. The formulation provides a convenient and effective antidiabetic therapy for controlling blood glucose levels without weight gain associated with other therapies.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP2498758
- Application Number
- EP10782113A
- Filing Date
- Nov 12, 2010
- Status
- Granted And Under Opposition
- Jun 22, 2018
- Publication Date
- Jul 25, 2018
- External Links
- Slate, Register , Google Patents